Redeye sees that BONESUPPORT is well-equipped to surpass its new 50% 2024e sales growth target, and we positively reconsider our US CERAMENT G open trauma sales rampup. Despite a lower-than-expected EBIT, the coming quarters should allow the company to demonstrate its excellent operating leverage more clearly. We up our fair value range somewhat.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/